Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 11/2016

01-07-2016 | Erratum

Erratum to: Reslizumab: First Global Approval

Author: Anthony Markham

Published in: Drugs | Issue 11/2016

Login to get access

Excerpt

Page 908, table entitled ‘Features and properties of reslizumab’ …
Metadata
Title
Erratum to: Reslizumab: First Global Approval
Author
Anthony Markham
Publication date
01-07-2016
Publisher
Springer International Publishing
Published in
Drugs / Issue 11/2016
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0608-x

Other articles of this Issue 11/2016

Drugs 11/2016 Go to the issue

Review Article

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Leading Article

Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm

Adis Drug Evaluation

Secukinumab: A Review in Psoriatic Arthritis

Review Article

Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management

AdisInsight Report

Migalastat: First Global Approval

AdisInsight Report

Olmutinib: First Global Approval